In an intention-to-treat analysis, the use of GLP-1RA was not associated with an increased risk of thyroid cancer compared with DPP-4i (adjusted HR: 0.81 [CI: 0.591.12]), and no trend was observed with increasing cumulative doses of GLP-1RA.
In the current study we found increased risk of all thyroid cancer and medullary thyroid cancer with use of GLP-1 RA, in particular after 13 years of treatment.
Such details provide a deeper understanding and appreciation for Glp-1 Receptor Agonists And Thyroid Cancer Treatment.
A: There is no evidence suggesting meaningful differences in thyroid cancer risk across different GLP-1 receptor agonists or dual GIP/GLP-1 agonists. The boxed warning applies to the class as a whole based on mechanism of action and rodent toxicology.
Researchers at the Clayman Thyroid Center recently released a White Paper evaluating whether glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) increased the risk of thyroid cancer in patients with type 2 diabetes and obesity. 1 The review aimed to clarify clinical misconceptions regarding the FDA boxed warning for GLP-1 ...
Mayo Clinic study finds no overall increase in thyroid cancer risk with GLP-1RA therapy, suggesting early diagnoses likely reflect detection bias, not causation.
Despite the lack of consistent clinical and epidemiological evidence, the potential link between GLP-1 receptor agonists and thyroid cancer has received considerable attention. Rodent studies have shown that treatment with liraglutide or once-weekly exenatide is associated with thyroid...
